Evolution of the Average Target: Lexeo Therapeutics, Inc.

Evolution of the Target Price: Lexeo Therapeutics, Inc.

Changes in Analyst Recommendations: Lexeo Therapeutics, Inc.

369e7f6960f29f07d0e.ki8PcWe8ajSV68gQI_MMAp0S1NeQXeDgxCmyhbelzaU.63tcNiLVHW6skoVXVZxvRPVfmbP-aIiMlHnGqO_sj8LCbWUUKcwwWubTow~8fa324d887e846696afea640fbde2a56
12-18 Raymond James Initiates Coverage on Lexeo Therapeutics With Strong Buy Rating, $25 Price Target MT
11-20 Cantor Fitzgerald Initiates Coverage on Lexeo Therapeutics With Overweight Rating, $19 Price Target MT
25-10-15 Guggenheim Initiates Coverage on Lexeo Therapeutics With Buy Rating, $30 Price Target MT
25-10-08 Chardan Raises Price Target on Lexeo Therapeutics to $17 From $15, Keeps Buy Rating MT
25-10-07 Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy CI
25-10-07 Lexeo Says FDA Open to Application Submission for Accelerated Approval of Friedreich Ataxia Cardiomyopathy Treatment MT
25-10-07 Lexeo Shares Rise On Progress for Heart Disease Treatment DJ
25-08-18 Chardan Cuts Price Target on Lexeo Therapeutics to $15 From $20, Keeps Buy Rating MT
25-07-31 Oppenheimer Initiates Lexeo Therapeutics at Outperform With $20 Price Target MT
25-05-13 Chardan Adjusts Price Target on Lexeo Therapeutics to $20 From $22, Maintains Buy Rating MT
25-04-08 Chardan Research Adjusts Lexeo Therapeutics Price Target to $22 From $25, Maintains Buy Rating MT
25-03-25 RBC Cuts Price Target on Lexeo Therapeutics to $20 From $24, Keeps Outperform, Speculative Risk MT
24-06-13 Baird Initiates Lexeo Therapeutics With Outperform Rating, $28 Price Target MT
24-06-06 HC Wainwright Initiates Lexeo Therapeutics at Buy With $22 Price Target MT
24-03-12 RBC Raises Price Target on Lexeo Therapeutics to $24 From $22, Cites 'Solid' Friedreich's Ataxia Data; Outperform, Speculative Risk Kept MT
23-11-28 Chardan Initiates Lexeo Therapeutics With Buy Rating, $23 Price Target MT
23-11-28 Stifel Starts Lexeo Therapeutics With Buy Rating, $20 Price Target MT
23-11-28 RBC Initiates Lexeo Therapeutics at Outperform, Speculative Risk With $22 Price Target Amid 'Undemanding' Valuation, Upcoming Catalysts MT
23-11-28 JPMorgan Starts Lexeo Therapeutics With Overweight Rating, $20 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+315.13%
+21.09%
+11.95%
+58.51%
+15.94%
+16.61%
+12.11%
+6.66%
+26.36%
-9.02%
Average +47.53%
Weighted average by Cap. +19.36%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
4.890USD
Average target price
20.30USD
Spread / Average Target
+315.13%
High Price Target
30.00USD
Spread / Highest target
+513.50%
Low Price Target
9.000USD
Spread / Lowest Target
+84.05%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
  1. Stock Market
  2. Stocks
  3. LXEO Stock
  4. Consensus Lexeo Therapeutics, Inc.